• Profile
Close

Hypomagnesemia during teriparatide treatment in osteoporosis: Incidence and determinants

Journal of Bone and Mineral Research Jun 01, 2018

Bégin MJ, et al. - In this retrospective cohort study, researchers sought to ascertain the incidence of hypomagnesemia (serum magnesium <0.7 mmol/L) associated with teriparatide and identify the predisposing factors to hypomagnesemia. Between May 2008 and January 2016, the files of 53 patients treated for severe osteoporosis with teriparatide for 6 to 24 months were reviewed. In patients treated with teriparatide for severe osteoporosis, a statistically significant decrease in the serum magnesium levels was observed. Significant determinants of hypomagnesemia were older age and lower baseline magnesium. The findings suggested that closer monitoring of serum magnesium level should be considered in patients treated with teriparatide for severe osteoporosis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay